Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine for KRAS-dependent advanced pancreatic ductal adenocarcinoma
2021-002632-23Phase 2Terminated
- Sponsor
- Istituti Fisioterapici Ospitalieri
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of decitabine in pancreatic adenocarcinoma (PDAC), sponsored by Istituti Fisioterapici Ospitalieri. Primary endpoint: Best Overall Response Rate (BOR). Started Sep 2021; status: terminated.
02
Drugs
decitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2021-002632-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002632-23.